Drug – bio-affecting and body treating compositions – Preparations characterized by special physical form – Tablets – lozenges – or pills
Reexamination Certificate
2001-02-15
2002-10-08
Page, Thurman K. (Department: 1615)
Drug, bio-affecting and body treating compositions
Preparations characterized by special physical form
Tablets, lozenges, or pills
C424S474000, C424S475000, C424S468000, C424S489000, C424S490000, C424S471000
Reexamination Certificate
active
06461639
ABSTRACT:
BACKGROUND OF THE INVENTION
1. Field of the Invention
This invention relates to a core formulation, and, more particularly, to a core formulation comprising a first layer comprising troglitazone, which covers at least a portion of a core comprising a biguanide, such as for example metformin (i.e., glucophage), with a modulating release polymer comprising of a polysacchaside, e.g. an alginate.
2. Description of the Related Art
Metformin and troglitazone, and their salts such as the hydrochlorides, maleates, tartrates, etc., are two active ingredients of anti-diabetic drugs that are used to treat diabetic patients, e.g. human beings. These two active agents are administered orally to patients in need thereof in protocols calling for the single administration of either ingredient. Heretofore, there has not been revealed or hinted at combining both ingredients and certainly not a physically combined core formulation comprising both ingredients. The advantage of such a core formulation is advantageous to patients and prescribers because both medicaments are synergistic to each other in the body when used in the management of blood glucose control, i.e., diabetes. Furthermore, the use of a modulating agent, like an alginate, in the preparation, controls the rate of drug release over a clinically meaningful period to enable better control of the effect of the medicinal agents in such preparation.
SUMMARY OF THE INVENTION
This invention relates to a core formulation, and, more particularly, to a core formulation comprising a first layer comprising troglitazone or a derivative thereof, e.g. troglitazone hydrochloride, which covers at least a portion of a core comprising a biguanide, one of both of which are intimately dispersed in a polysacchaside modulating release agent, e.g. an alginate.
REFERENCES:
patent: 4389330 (1983-06-01), Tice et al.
patent: 6030641 (2000-02-01), Yamashita et al.
patent: 6166042 (2000-12-01), Ikeda et al.
patent: 6296874 (2001-10-01), Cutie et al.
Adjei Akwete L.
Cutie Anthony J.
Zhu Yaping
Aeropharm Technology Inc.
Frommer & Lawrence & Haug LLP
Joynes Robert M.
LandOfFree
Core formulation does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Core formulation, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Core formulation will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2997517